Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo
暂无分享,去创建一个
Omid C Farokhzad | Stephen J Lippard | Shanta Dhar | O. Farokhzad | S. Lippard | S. Dhar | Nagesh Kolishetti | N. Kolishetti | Nagesh Kolishetti
[1] Xiaoling Zhang,et al. Molecular Assembly of an Aptamer–Drug Conjugate for Targeted Drug Delivery to Tumor Cells , 2009, Chembiochem : a European journal of chemical biology.
[2] M D Blaufox,et al. Blood volume in the rat. , 1985, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[3] M. Jakupec,et al. Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches. , 2005, Current medicinal chemistry.
[4] Dong Wang,et al. Cellular processing of platinum anticancer drugs , 2005, Nature Reviews Drug Discovery.
[5] V. Reuter,et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. , 1999, Cancer research.
[6] Robert Langer,et al. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA–PEG nanoparticles , 2008, Proceedings of the National Academy of Sciences.
[7] J. Nakayama,et al. Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. , 1997, Cancer research.
[8] Eric Pridgen,et al. Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles , 2008, Molecular pharmaceutics.
[9] S. Lippard,et al. Structure, Recognition, and Processing of Cisplatin-DNA Adducts. , 1999, Chemical reviews.
[10] Robert Langer,et al. Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy , 2010, Proceedings of the National Academy of Sciences.
[11] A. Karydas,et al. PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. , 2002, Journal of controlled release : official journal of the Controlled Release Society.
[12] Robert Langer,et al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers , 2008, Proceedings of the National Academy of Sciences.
[13] Robert J. Lee,et al. Targeted drug delivery via folate receptors. , 2008, Expert opinion on drug delivery.
[14] S. Lippard,et al. Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate , 2009, Proceedings of the National Academy of Sciences.
[15] M. Roberts,et al. In vivo investigation of tolerance and antitumor activity of cisplatin-loaded PLGA-mPEG nanoparticles. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[16] Shuming Nie,et al. Development of multifunctional nanoparticles for targeted drug delivery and noninvasive imaging of therapeutic effect. , 2009, Current drug discovery technologies.
[17] S. Lippard,et al. Conjugated platinum(IV)-peptide complexes for targeting angiogenic tumor vasculature. , 2008, Bioconjugate chemistry.
[18] W. Fair,et al. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. , 1993, Cancer research.
[19] V. Torchilin,et al. Biodegradable long-circulating polymeric nanospheres. , 1994, Science.
[20] Y. Ci,et al. Pharmacokinetics and tissue distribution of iv injection of polyphase liposome-encapsulated cisplatin (KM-1) in rats. , 2003, Acta pharmacologica Sinica.
[21] Robert Langer,et al. An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. , 2006, Angewandte Chemie.
[22] F. Gu,et al. Formulation/preparation of functionalized nanoparticles for in vivo targeted drug delivery. , 2009, Methods in molecular biology.
[23] D. Nie,et al. Human pregnane X receptor and resistance to chemotherapy in prostate cancer. , 2007, Cancer research.
[24] Z. Siddik,et al. Comparative distribution and excretion of carboplatin and cisplatin in mice , 1988, Cancer Chemotherapy and Pharmacology.
[25] H. Dai,et al. Targeted single-wall carbon nanotube-mediated Pt(IV) prodrug delivery using folate as a homing device. , 2008, Journal of the American Chemical Society.
[26] D. Bostwick,et al. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen , 1998, Cancer.
[27] P. Schellhammer,et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. , 1996, Urology.
[28] J. Richie,et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[29] J. Trosko,et al. Platinum Compounds: a New Class of Potent Antitumour Agents , 1969, Nature.